Company Dossier · Health Care
Steris
- S&P 500
- Russell 1000
What Steris is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $6.04 billion, up 8.4% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $0.93 billion, up 2.2% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2026: $0.36 billion, about level with a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to March 31, 2026: $0.24 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (August 6, 2026): sentiment 0.20 on a −1 to +1 scale (mixed), confidence 0.70 of 1.Palanor Discourse
- Guidance in the last 90 days: 1 outlook figure raised, 1 lowered, 2 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed May 29, 2026): 1 risk factor added, 3 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $1.0 million on the open market.SEC Form 4
- 837 institutional managers reported a position at June 30, 2026 (−7 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 8 (8 a year earlier).U.S. Department of Labor (OFLC)
Risk events (12 months): 1 — latest OSHA inspection, Jul 27, 2026 →
Company Posture
How Company Posture is measured →What Steris is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.
Steady · Mixed
Expanding ↔ Retrenching
Steady
- Capital spending54th pct
- Debt raised—
- Buybacks vs capex45th pct
- Hiring filings42nd pct
- Deals and private raises49th pct
- Patent publications94th pct
Confident ↔ Hedging
Mixed
- Call sentiment35th pct
- Call confidence41st pct
- Guidance changes31st pct
- Risk factors added37th pct
- Insider open-market trades44th pct
- − Guidance changes
- − Call sentiment
- − Risk factors added
Pressure
Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).
- Fails-to-deliver5th pct
- Stress filings48th pct
Credit
How these are built →Steris's borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.
Debt on the balance sheet
$1.9B
- Due within a year $0.2B
- Longer term $1.7B
- Default point $1.1B (short + ½ long)
Finance leases included · Jun 30, 2026 filing
Bonds priced, last 12 months
None
U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Steris: earnings call confidence
Palanor Discourse score per call, 0 to 1
Hiring and ownership
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 20, 2026LobbyingLobbying report (THORN RUN PARTNERS)third_quarter 2026 · $0.0 million
- Oct 20, 2026Patent
- Oct 18, 2026LobbyingLobbying report (JEFFREY J. KIMBELL AND ASSOCIATES)third_quarter 2026 · $0.0 million
- Oct 14, 2026LobbyingLobbying report (STERIS CORPORATION)third_quarter 2026 · $0.1 million
- Oct 13, 20268-KMaterial agreement signedItem 1.01
- Oct 13, 2026Patent
- Sep 22, 2026PatentPatent granted: Foam FormulationsUS 12742135
- Sep 15, 2026Patent
- Sep 1, 2026Patent
- Aug 6, 20268-KShareholder vote resultsItem 5.07
- Aug 6, 20268-KDirector or officer changeItem 5.02
- Aug 5, 20268-KExit or restructuring costsItem 2.05
- Jul 27, 2026Risk event
- Jul 20, 2026LobbyingLobbying report (STERIS CORPORATION)second_quarter 2026 · $0.1 million
- Jul 20, 2026LobbyingLobbying report (JEFFREY J. KIMBELL & ASSOCIATES, INC.)second_quarter 2026 · $0.0 million
- Jul 20, 2026LobbyingLobbying report (THORN RUN PARTNERS)second_quarter 2026 · $0.1 million
- May 29, 202610-KAnnual report (10-K)1 risk factors added, 3 removed
- May 7, 20268-KDirector or officer changeItem 5.02
- Apr 20, 2026LobbyingLobbying report (JEFFREY J. KIMBELL & ASSOCIATES, INC.)first_quarter 2026 · $0.0 million
- Apr 20, 2026LobbyingLobbying report (STERIS CORPORATION)first_quarter 2026 · $0.1 million
- Apr 6, 20268-KDirector or officer changeItem 5.02
- Aug 6, 20258-KDirector or officer changeItem 5.02
- Aug 6, 20258-KShareholder vote resultsItem 5.07
- Jul 3, 20258-KDirector or officer changeItem 5.02
- May 29, 202510-KAnnual report (10-K)0 risk factors added, 1 removed
- May 29, 202410-KAnnual report (10-K)1 risk factors added, 1 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| ResMed| RMD | $5.7B | $1.6B | Jun 30, 2026 |
| Edwards Lifesciences EW | $6.5B | $1.4B | Jun 30, 2026 |
| Dexcom DXCM | $5.0B | $1.4B | Jun 30, 2026 |
| Idexx Laboratories IDXX | $4.5B | $1.3B | Jun 30, 2026 |
| Zimmer Biomet ZBH | $8.5B | $1.5B | Jun 30, 2026 |
| Bruker BRKR | $3.5B | $0.1B | Jun 30, 2026 |
| Intuitive Surgical ISRG | $11.0B | $3.2B | Jun 30, 2026 |
| Baxter International BAX | $11.5B | — | Jun 30, 2026 |